Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis

Area of Science:

• Hepatology
• Metabolic Diseases
• Clinical Trials

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of chronic liver disease globally.
• Prevalence has increased over 50% in the last 30 years, impacting up to one-third of the population.
• Projected increases in decompensated cirrhosis and liver cancer by 2030 due to rising MASLD rates.

Purpose of the Study:

• To review recent breakthroughs in phase 3 clinical trials for MASLD.
• To discuss emerging developments and future therapeutic horizons for MASLD.
• To address challenges in patient identification and treatment effectiveness assessment in real-world settings.

Main Methods:

• Review of phase 3 clinical trial data for MASLD therapies.
• Analysis of current trends and projections for MASLD progression.
• Discussion of clinical and real-world evidence challenges.

Main Results:

• Two major breakthroughs in phase 3 trials indicate the imminent availability of licensed MASLD therapies.
• Significant advancements are on the horizon for treating this complex liver disease.
• Key challenges remain in patient selection and outcome measurement.

Conclusions:

• The landscape of MASLD treatment is poised for transformation with new licensed therapies.
• Effective strategies for patient stratification and real-world outcome evaluation are crucial.
• Continued research and clinical evaluation are essential to combat the growing burden of MASLD.